nach oben

Breast Cancer Research

Erschienen in:

01.10.2001 | Review

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

verfasst von: Michael John Fry

Erschienen in: Breast Cancer Research | Ausgabe 5/2001

Einloggen, um Zugang zu erhalten

Abstract

Phosphoinositide 3-kinase (PI3K) was first identified as a lipid kinase activity associated with the products of viral oncogenes and with activated protein-tyrosine kinases. Since those early studies, the PI3K superfamily has grown to embrace at least 12 structurally and functionally related enzymes present in the human genome, some of which have protein kinase activity but not lipid kinase activity. Evidence is emerging that PI3K superfamily members, and components of PI3K signalling, play a role in the development of many human cancers. In this review, the PI3K family of enzymes and their signalling is reviewed, with particular reference to possible involvement in breast cancer.

Fry MJ: Structure, regulation and function of phosphoinositide 3-kinases. Biochem Biophys Acta. 1994, 1226: 237-268. 10.1016/0925-4439(94)90036-1.PubMed

Roymans D, Slegers H: Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem. 2001, 268: 487-498. 10.1046/j.1432-1327.2001.01936.x.CrossRefPubMed

Leevers SJ, Vanhaesebroeck B, Waterfield MD: Signalling through phosphoinositide 3-kinase: the lipids take centre stage. Curr Opin Cell Biol. 1999, 11: 219-225. 10.1016/S0955-0674(99)80029-5.CrossRefPubMed

Stein RC, Waterfield MD: PI3-kinase inhibition: a target for drug development?. Mol Med Today. 2000, 6: 347-357. 10.1016/S1357-4310(00)01770-6.CrossRefPubMed

Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999, 253: 239-254. 10.1006/excr.1999.4701.CrossRefPubMed

Kastan MB, Lim DS: The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000, 1: 179-186. 10.1038/35043058.CrossRefPubMed

Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, Domin J: Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol. 2000, 20: 3817-3830. 10.1128/MCB.20.11.3817-3830.2000.CrossRefPubMedPubMedCentral

Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC, Waterfield MD: Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J. 1997, 326: 139-147.CrossRefPubMedPubMedCentral

Brown RA, Ho LKF, Weber-Hall SJ, Shipley JM, Fry MJ: Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem Biophys Res Commun. 1997, 233: 537-544. 10.1006/bbrc.1997.6495.CrossRefPubMed

10.

Ho LKF, Liu D, Rozycka M, Brown RA, Fry MJ: Identification of four novel human phosphoinositide 3-kinase defines a multi-isoform subfamily. Biochem Biophys Res Commun. 1997, 235: 130-137. 10.1006/bbrc.1997.6747.CrossRefPubMed

11.

Rozycka M, Lu YJ, Brown RA, Lau MR, Shipley JM, Fry MJ: cDNA cloning of a third human C2 domain-containing Class II phosphoinositide 3-kinase, PI3K-C2γ, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics. 1998, 54: 569-574. 10.1006/geno.1998.5621.CrossRefPubMed

12.

Odorizzi G, Babst M, Emr SD: Phosphoinositide signalling and regulation of membrane trafficking in yeast. Trends Biochem Sci. 2000, 25: 229-235. 10.1016/S0968-0004(00)01543-7.CrossRefPubMed

13.

Siddhanta U, McIlroy J, Shah A, Zhang YT, Backer JM: Distinct roles for the p110alpha and hVPS34 phosphatidylinositol 3'-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis. J Cell Biol. 1998, 143: 1647-1659. 10.1083/jcb.143.6.1647.CrossRefPubMedPubMedCentral

14.

Dennis PB, Fumagalli S, Thomas G: Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev. 1999, 9: 49-54. 10.1016/S0959-437X(99)80007-0.CrossRefPubMed

15.

Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindley GB, Rutherford PG, Gallegos A, Massey K, Powis G: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 1995, 15: 1135-1139.PubMed

16.

Price BD, Youmell MB: The phosphatidylinositol 3-kinase inhibitor wortmannin sensitises murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996, 56: 246-250.PubMed

17.

Davol PA, Bizuneh A, Frackelton AR: Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo. Anti-cancer Res. 1999, 19: 1705-1713.

18.

Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G: Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmocol. 1999, 44: 491-497. 10.1007/s002800051123.CrossRef

19.

Vazquez F, Sellers WR: The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signalling. Biochem Biophys Acta. 2000, 1470: M21-M35. 10.1016/S0304-419X(99)00032-3.PubMed

20.

Kandel ES, Hay N: The regulation and activities of the multi-functional serine/threonine kinase Akt/PKB. Exp Cell Res. 1999, 253: 210-229. 10.1006/excr.1999.4690.CrossRefPubMed

21.

Ma Y-Y, Wei S-J, Lin Y-C, Lung J-C, Chang T-C, Whang-Peng J, Liu JM, Yang D-M, Yang WK, Shen C-Y: PIK3CA as an oncogene in cervical cancer. Oncogene. 2000, 19: 2739-2744. 10.1038/sj/onc/1203597.CrossRefPubMed

22.

Aoki M, Blazek E, Vogt PK: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3K and Akt. Proc Natl Acad Sci USA. 2001, 98: 136-141. 10.1073/pnas.011528498.CrossRefPubMed

23.

Alexandre J, Raymond E, Armand JP: Rapamycin and CCI-779. Bull Cancer. 1999, 86: 808-811.PubMed

24.

Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE, Krasil'nikov MA: Phosphatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta. 1999, 287: 59-67. 10.1016/S0009-8981(99)00118-7.CrossRefPubMed

25.

Amundadottir LT, Leder P: Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene. 1998, 16: 737-746. 10.1038/sj/onc/1201829.CrossRefPubMed

26.

Webster MA, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton M, Tortorice CG, Cardiff RD, Graham FL, Hassell JA, Muller WJ: Requirement for both Shc and phosphatidylinositol 3' kinase signalling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol. 1998, 18: 2344-2359.CrossRefPubMedPubMedCentral

27.

Kim HH, Sierke SL, Koland JG: Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem. 1994, 269: 24747-24755.PubMed

28.

Ram TG, Ethier SP: Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Diff. 1996, 7: 551-561.PubMed

29.

Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW: Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res. 1999, 59: 5475-5478.PubMed

30.

Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP: ERBB-2 overexpression confers PI 3' kinase dependent invasion capacity on human mammary epithelial cells. Br J Cancer. 2000, 82: 666-674. 10.1054/bjoc.1999.0979.CrossRefPubMedPubMedCentral

31.

Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ: Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000, 2: 203-210. 10.1186/bcr55.CrossRefPubMedPubMedCentral

32.

Barker KT, Jackson LE, Crompton MR: BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene. 1997, 15: 799-805. 10.1038/sj/onc/1201241.CrossRefPubMed

33.

Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ, Page MJ, Gusterson BA, Crompton MR: Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitises mammary epithelial cells to epidermal growth factor. J Biol Chem. 1996, 271: 30956-30963. 10.1074/jbc.271.48.30956.CrossRefPubMed

34.

Kamalati T, Jolin HE, Fry MJ, Crompton MR: Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene. 2000, 19: 5471-5476. 10.1038/sj/onc/1203931.CrossRefPubMed

35.

Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C: Immuno-histochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999, 155: 1253-1260.CrossRefPubMedPubMedCentral

36.

Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R, Varmus HE: Deficiency of pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol. 2001, 2: 2-10.1186/1471-2199-2-2.CrossRefPubMedPubMedCentral

37.

Weng L-P, Brown JL, Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet. 2001, 10: 237-242. 10.1093/hmg/10.3.237.CrossRefPubMed

38.

Nakatomi K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem. 1999, 274: 21528-21532. 10.1074/jbc.274.31.21528.CrossRef

39.

Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 1998, 273: 29864-29872. 10.1074/jbc.273.45.29864.CrossRefPubMed

40.

Dufourny B, van Teeffelen HA, Hamelers IH, Sussenbach JS, Steenbergh PH: Stabilisation of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. Endocrinology. 2000, 166: 329-338.CrossRef

41.

Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ: Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001, 21: 2203-2212. 10.1128/MCB.21.6.2203-2212.2001.CrossRefPubMedPubMedCentral

42.

Altiok S, Batt D, Altiok N, Papautsky A, Downward J, Roberts TM, Avraham H: Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells. J Biol Chem. 1999, 274: 32274-32278. 10.1074/jbc.274.45.32274.CrossRefPubMed

43.

Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996, 92: 130-134. 10.1016/S0165-4608(96)00328-7.CrossRefPubMed

44.

FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA: Heterozygous ATM mutations do not contribute to early onset breast cancer. Nat Genet. 1997, 15: 307-310.CrossRefPubMed

45.

Gatti RA, Tward A, Concannon P: Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 1999, 68: 419-423. 10.1006/mgme.1999.2942.CrossRefPubMed

46.

Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double strand breaks. Science. 1999, 286: 1162-1166. 10.1126/science.286.5442.1162.CrossRefPubMed

47.

Chen J: Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res. 2000, 60: 5037-5039.PubMed

48.

Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK: Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phosphospecific antibodies. J Biol Chem. 2001, 276: 17276-17280. 10.1074/jbc.M011681200.CrossRefPubMed

49.

Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, Lee EY, Lee WH: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature. 2000, 406: 210-215. 10.1038/35018134.CrossRefPubMed

50.

Baldi A, Boyle DM, Wittliff JL: Estrogen receptor is associated with protein and phospholipid kinase activities. Biochem Biophys Res Commun. 1986, 135: 597-606.CrossRefPubMed

51.

Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000, 407: 538-541. 10.1038/35035131.CrossRefPubMedPubMedCentral

52.

Ahmad S, Singh N, Glazer RI: Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-1)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol. 1999, 58: 425-430. 10.1016/S0006-2952(99)00125-2.CrossRefPubMed

53.

Lobenhofer EK, Huper G, Iglehart JD, Marks JR: Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Diff. 2000, 11: 99-110.PubMed

54.

Razandi M, Pedram A, Levin ER: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol. 2000, 14: 1434-1447. 10.1210/me.14.9.1434.CrossRefPubMed

55.

Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A: A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology. 2000, 141: 4503-4511. 10.1210/en.141.12.4503.CrossRefPubMed

56.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: PI3 kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001, 276: 9817-9824. 10.1074/jbc.M010840200.CrossRefPubMed

Titel: Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
verfasst von: Michael John Fry
Publikationsdatum: 01.10.2001
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 5/2001
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr312

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2001

The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression

Mutations in normal breast tissue and breast tumours

Hypoxia and oxidative stress in breast cancer Hypoxia and tumourigenesis

Hypoxia and oxidative stress in breast cancer Oxidative stress - its effects on the growth, metastatic potential and response to therapy of breast cancer

Characterization of adjacent breast tumors using oligonucleotide microarrays

Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12-15 May 2001

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie